vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and POTLATCHDELTIC CORP (PCH). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $314.2M, roughly 1.9× POTLATCHDELTIC CORP). EXELIXIS, INC. runs the higher net margin — 40.8% vs 8.2%, a 32.6% gap on every dollar of revenue. On growth, POTLATCHDELTIC CORP posted the faster year-over-year revenue change (23.1% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $50.1M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 11.1%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
POTLATCHDELTIC CORPPCHEarnings & Financial Report
PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.
EXEL vs PCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $314.2M |
| Net Profit | $244.5M | $25.9M |
| Gross Margin | 95.6% | 18.2% |
| Operating Margin | 39.3% | 11.2% |
| Net Margin | 40.8% | 8.2% |
| Revenue YoY | 5.6% | 23.1% |
| Net Profit YoY | 74.8% | 682.5% |
| EPS (diluted) | $0.89 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | — | ||
| Q3 25 | $568.3M | $314.2M | ||
| Q2 25 | $555.4M | $275.0M | ||
| Q1 25 | $566.8M | $268.3M | ||
| Q4 24 | — | $258.1M | ||
| Q3 24 | $539.5M | $255.1M | ||
| Q2 24 | $637.2M | $320.7M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | — | ||
| Q3 25 | $184.8M | $25.9M | ||
| Q2 25 | $159.6M | $7.4M | ||
| Q1 25 | $139.9M | $25.8M | ||
| Q4 24 | — | $5.2M | ||
| Q3 24 | $118.0M | $3.3M | ||
| Q2 24 | $226.1M | $13.7M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | 18.2% | ||
| Q2 25 | 96.5% | 13.0% | ||
| Q1 25 | 96.5% | 17.8% | ||
| Q4 24 | — | 13.4% | ||
| Q3 24 | 96.8% | 10.8% | ||
| Q2 24 | 97.2% | 11.9% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | — | ||
| Q3 25 | 37.6% | 11.2% | ||
| Q2 25 | 33.6% | 5.0% | ||
| Q1 25 | 28.8% | 10.3% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | 25.2% | 2.8% | ||
| Q2 24 | 43.3% | 5.4% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | — | ||
| Q3 25 | 32.5% | 8.2% | ||
| Q2 25 | 28.7% | 2.7% | ||
| Q1 25 | 24.7% | 9.6% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | 21.9% | 1.3% | ||
| Q2 24 | 35.5% | 4.3% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | — | ||
| Q3 25 | $0.65 | $0.33 | ||
| Q2 25 | $0.55 | $0.09 | ||
| Q1 25 | $0.47 | $0.33 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $0.40 | $0.04 | ||
| Q2 24 | $0.77 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $88.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $1.9B |
| Total Assets | $2.8B | $3.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | $88.8M | ||
| Q2 25 | $1.0B | $95.3M | ||
| Q1 25 | $1.1B | $147.5M | ||
| Q4 24 | — | $151.6M | ||
| Q3 24 | $1.2B | $161.1M | ||
| Q2 24 | $1.0B | $199.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.0B | $1.9B | ||
| Q2 25 | $2.1B | $1.9B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $2.3B | $2.1B | ||
| Q2 24 | $2.1B | $2.1B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | $3.2B | ||
| Q2 25 | $2.8B | $3.2B | ||
| Q1 25 | $2.9B | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | $3.0B | $3.3B | ||
| Q2 24 | $2.8B | $3.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $65.7M |
| Free Cash FlowOCF − Capex | $332.4M | $50.1M |
| FCF MarginFCF / Revenue | 55.5% | 15.9% |
| Capex IntensityCapex / Revenue | 0.2% | 4.9% |
| Cash ConversionOCF / Net Profit | 1.36× | 2.54× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $132.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | — | ||
| Q3 25 | $49.0M | $65.7M | ||
| Q2 25 | $211.4M | $41.0M | ||
| Q1 25 | $240.3M | $49.1M | ||
| Q4 24 | — | $45.4M | ||
| Q3 24 | $271.3M | $26.5M | ||
| Q2 24 | $119.5M | $100.6M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | $50.1M | ||
| Q2 25 | $208.5M | $30.6M | ||
| Q1 25 | $236.3M | $26.3M | ||
| Q4 24 | — | $25.4M | ||
| Q3 24 | $263.1M | $-8.2M | ||
| Q2 24 | $113.0M | $72.4M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | 15.9% | ||
| Q2 25 | 37.5% | 11.1% | ||
| Q1 25 | 41.7% | 9.8% | ||
| Q4 24 | — | 9.9% | ||
| Q3 24 | 48.8% | -3.2% | ||
| Q2 24 | 17.7% | 22.6% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | 4.9% | ||
| Q2 25 | 0.5% | 3.8% | ||
| Q1 25 | 0.7% | 8.5% | ||
| Q4 24 | — | 7.7% | ||
| Q3 24 | 1.5% | 13.6% | ||
| Q2 24 | 1.0% | 8.8% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | 2.54× | ||
| Q2 25 | 1.32× | 5.58× | ||
| Q1 25 | 1.72× | 1.90× | ||
| Q4 24 | — | 8.74× | ||
| Q3 24 | 2.30× | 7.99× | ||
| Q2 24 | 0.53× | 7.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PCH
| Lumber | $131.8M | 42% |
| Timberlands | $52.5M | 17% |
| Rural Real Estate | $51.3M | 16% |
| Residuals And Panels | $34.0M | 11% |
| Pulpwood | $16.7M | 5% |
| Development Real Estate | $14.6M | 5% |
| Other | $8.1M | 3% |
| Other Products | $5.2M | 2% |
